Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs ATYR-1923 (Primary)
  • Indications Pulmonary sarcoidosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors aTyr Pharma
  • Most Recent Events

    • 16 Jan 2019 According to an aTyr Pharma media release, recognized the collaboration between its Hong Kong subsidiary, Pangu BioPharma (Pangu), and The Hong Kong University of Science and Technology (HKUST) for contributions leading to the discovery of ATYR1923.
    • 04 Dec 2018 According to an aTyr Pharma media release, the Company's investigational new drug application for ATYR1923 has been approved by the US Food and Drug Administration. This trial is being conducted in collaboration with the Foundation for Sarcoidosis Research (FSR) and FSR will assist with clinical trial site initiation and patient enrollment.
    • 04 Dec 2018 Status changed from planning to recruiting, as reported in an aTyr Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top